FEB 21, 2017 11:44 AM PST

TSRI-Invented Compound Ozanimod Shows Positive Results in Late-Stage Clinical Trial for Relapsing Multiple Sclerosis

Image Credit: Pixabay

February 21, 2017 – Results from a new Phase 3 study conducted by the Celgene Corporation demonstrate that ozanimod, a drug candidate originally discovered and optimized at The Scripps Research Institute (TSRI), can reduce the frequency of multiple sclerosis relapse.

Relapsing multiple sclerosis is a form of the disease where patients experience a periodic worsening of symptoms. Sensory and motor loss of function leads to increased disability, and patients can need a cane or wheelchair. A signature of the disease is the appearance of lesions in the brain, which are linked to inflammation and can show up through MRI detection during active periods of multiple sclerosis relapse.

Ozanimod, discovered by TSRI Professors Hugh Rosen and Ed Roberts and their laboratories, acts as a sphingosine 1-phosphate 1 (S1PR1) receptor agonist—modulating S1PR1 signaling and blocking sources of inflammation. Rosen and Roberts went on to co-found Receptos, a clinical stage biopharmaceutical company that took ozanimod into Phase 1, 2 and 3 clinical trials and was then acquired by Celgene. Ozanimod is the first New Chemical Entity discovered from a starting point in the NIH Common Fund Molecular Libraries Initiative to reach and succeed in advanced clinical studies.

As reported by Celgene, results from the randomized, Phase 3, double-blind, double-dummy, active-controlled SUNBEAM study among 1,346 participants show that ozanimod met its primary endpoint in reducing annualized relapse rate (ARR) of relapsing multiple sclerosis, compared with an alternate drug treatment called weekly interferon (IFN) β-1a (Avonex®).

Administered at doses of both 1 mg and 0.5 mg, ozanimod demonstrated statistically significant and clinically meaningful improvements, compared to Avonex®, for the primary endpoint of ARR and the measured secondary endpoints of the number of MRI-detected lesions and the number of new or enlarging “T2” MRI lesions at after a year of treatment.

“It is exciting and rewarding to see the results of this new Phase 3 trial, which confirm the safety profile from the two-year extension data from the Phase 2 RADIANCE study and underscore ozanimod’s efficacy in reducing the burden of MS symptoms on patients and their families,” said Rosen. “We look forward to seeing the full study results, as well as the results from the Phase 3 study evaluating ozanimod in patients with ulcerative colitis.”

Scientists involved in the trial plan to present the full Phase 3 trial results at an upcoming international scientific meeting.

This article was originally published on Scripps.edu.

About the Author
  • The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists-including two Nobel laureates-work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
You May Also Like
FEB 03, 2020
Neuroscience
FEB 03, 2020
Genetic Characterization of Bipolar Disorders, Major Depressive Disorder
Mood disorders, like Bipolar, Major Depressive Disorder, and Schizophrenia, among others, are difficult to define clinically.  Unlike disorders that a...
FEB 14, 2020
Microbiology
FEB 14, 2020
CDC Director Expects Coronavirus to Find a "Foothold"
The novel coronavirus that emerged in Wuhan, Hubei Province, China has now infected over 64,000 people....
FEB 16, 2020
Cell & Molecular Biology
FEB 16, 2020
Growing Cells on Scaffolding as an Alternative to Animal Models
Researchers may have just made it easier for investigators to switch to an engineered model and replace their animal colonies with electrospun synthetics....
FEB 19, 2020
Microbiology
FEB 19, 2020
Cases of Coronavirus SARS-CoV-2 Start to Rise Outside of China
The novel coronavirus that recently emerged in Hubei province, China is called SARS-CoV-2, and it can cause a wide range of symptoms....
FEB 21, 2020
Health & Medicine
FEB 21, 2020
Should You Really be Scared of the Coronavirus?
As of February 21st, the death toll for coronavirus reached 2,250, 55,707 currently infected, of which 12,066 (22%) are in a serious or critical condition....
FEB 21, 2020
Clinical & Molecular DX
FEB 21, 2020
Diagnosing COVID-19
Diagnosing coronavirus is done through next-generation sequencing, real-time RT-PCR tests, cell culture, and electron miscopy. For patients, that translate...
Loading Comments...